$-0.40 EPS Expected for Ritter Pharmaceuticals, Inc. (RTTR)

May 7, 2018 - By Migdalia James

Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.40 EPS on May, 8.They anticipate $1.00 EPS change or 71.43 % from last quarter’s $-1.4 EPS. After having $-1.10 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -63.64 % EPS growth. The stock increased 2.78% or $0.08 during the last trading session, reaching $2.96. About 33,576 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 85.20% since May 7, 2017 and is downtrending. It has underperformed by 96.75% the S&P500.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $14.62 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

More important recent Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) news were published by: Benzinga.com which released: “32 Biggest Movers From Yesterday” on April 18, 2018, also Seekingalpha.com published article titled: “Your Daily Pharma Scoop: Alnylam Update, Malinckrodt’s Adcom Failure, Anika’s Drug Recall”, Streetinsider.com published: “UPDATE: Ritter Pharma (RTTR) Agrees to Conduct 1st of 2 Pivotal Phase 3 Clinical Trials for RP-G28 with Medpace” on May 03, 2018. More interesting news about Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was released by: Benzinga.com and their article: “41 Biggest Movers From Yesterday” with publication date: April 13, 2018.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.